Bharat Biotech’s Covaxin gets authorisation for emergency use: V K Paul
Bharat Biotech’s Covaxin has been given the regular emergency use authorisation in public interest, putting it on a par with the approval granted to Serum Institute’s Covishield’s, V K Paul, member-health, Niti Aayog told reporters on Thursday.
Health Secretary Rajesh Bhushan added that the government has renegotiated the price of vaccines at a much lower level than before, without sharing any further details. “Earlier price was Rs 200 per dose and Rs 210 with taxes. After that, the re-negotiated price is significantly lower than this.”
Paul added: “Covaxin is now allowed for restricted use in emergency usage in public interest. The vaccine has stood the test of time in terms of great safety. Covaxin is now in regular emergency use authorisation, the same as Covishield,” Paul told reporters.
In January, Covaxin was given restricted use authorisation under clinical trial mode with abundant precaution. With interim data for phase-3 trials showing an efficacy of 81 per cent, Covaxin would not have to be administered in “clinical trial” mode anymore.
“It is the triumph for India’s research and development enterprise and science and technology enterprise,” Paul said.
The Subject Expert Panel on COVID-19 of the CDSCO had recommended granting emergency use authorisation to Bharat Biotech’s indigenously developed Covaxin while removing the condition for the vaccine to be administered in “clinical trial mode”.
So far 1.9 million people in the country have been given Covaxin, of whom 311 showed some side effects.
More than 18 million people have received Serum Institutes’s Covishield vaccine, according to data available on the CoWIN portal.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
